Major depressive disorder (MDD) is a leading contributor to the global burden of disease. However, the causal relationship of risk factors, such as genetic predisposition or experience of augmented stress, remain unknown. Numerous studies in humans and rodents have implicated brain-derived neurotrophic factor (BDNF) in MDD pathology, as a genetic risk factor and a factor regulated by stress. Until now, the majority of preclinical studies have employed genetically modified mice as their model of choice. However, mice display a limited behavioural repertoire and lack expression of circulating BDNF, which is present in rats and humans. Therefore, heterozygous BDNF (BDNF +/− ) rats were tested for affective behaviours and accompanying expression of key genes associated with affective disorders in the brain. We found that BDNF +/− rats, which have reduced BDNF levels in brain and plasma, displayed symptoms of anhedonia, a core symptom of MDD, and anxiety-like behaviour, but no behavioural despair or cognitive impairments. This was accompanied by changes in the expression of genes that are implicated in modulation of the stress response and affective disorders. Hence, glucocorticoid receptor, neuregulin 1 and disrupted-in-schizophrenia 1 gene expression were upregulated in the prefrontal cortex of BDFN +/− rats, whereas FK506 binding protein 5 levels were decreased in the hippocampus. We conclude that a reduction in BDNF levels alters expression of genes associated with affective disorders, which may contribute to the development of depressive-like symptoms.
| INTRODUCTION
Major depressive disorder (MDD) is the leading cause of disability worldwide affecting 300 million people and their socio-economic environment. 1 Stressful life events, such as sustained stress load at work or family disharmony, can trigger MDD development, in particular in predisposed individuals. [2] [3] [4] [5] By implication, MDD pathology emerges from a gene x environment interaction eliciting a heterogeneity of symptoms. 6 Heritability of MDD is presumed to be 30%-40%. 7 However, many genes which exert small effects on their own may interact to contribute to the overall pathogenesis of MDD 8 ; confounding the identification of MDD-specific candidate genes. Furthermore, MDD patients display high comorbidities with other neuropsychiatric diseases, such as anxiety disorders, which additionally enhances the complexity of MDD. 9, 10 Hence, the aetiology of MDD pathogenesis is still insufficiently understood, which precludes the tailoring of antidepressant treatment and reduces drug efficacy.
Brain-derived neurotrophic factor (BNDF), involved in neural circuit function and plasticity, 11 was identified as a possible contributor to MDD pathogenesis and drug efficacy. 12, 13 In humans, the BDNF polymorphism Val66Met, linked to reduced BDNF activity, 14,15 was shown to have a strong interaction with stressful life events in MDD pathogenesis. 15 Moreover, stress, which is known as a major environmental risk factor for MDD development across species, 3, 4, 16 reduces Megan C. Holmes and Anjanette P. Harris are joint senior authors in this study.
BDNF levels in the hippocampus (HPC) in preclinical studies. 17, 18 The HPC is a brain region that also shows reduced plasticity in environmentally-induced preclinical MDD models 19 and atrophy in humans with MDD. 20 Furthermore, reduced BDNF levels in prefrontal cortex (PFC) and HPC were found in post-mortem tissue of MDD patients 21 ; whereas MDD patients medicated with antidepressants showed elevated BDNF levels in the HPC post-mortem. 22 Similarly, serum BDNF was decreased in depressed patients and elevated following medication. 13, 23, 24 Moreover in preclinical studies, infusion of BDNF in the midbrain induced an antidepressant-like effect in the learned helplessness paradigm 25 and antidepressant drug efficacy was shown to be BDNF level dependent. [26] [27] [28] Hence, these findings promoted preclinical research into MDD using mice with genetically reduced BDNF expression.
However, these preclinical studies resulted in inconsistent findings with genetically-reduced levels of BDNF provoking depressivelike phenotypes in only a limited proportion of mouse studies. [28] [29] [30] One possible explanation may be that mice, unlike humans and rats, do not express peripheral BDNF. 31 Peripheral administration of BDNF in mice altered gene expression in the brain and produced an antidepressant-like and anxiolytic behavioural response, although the precise mechanism of action remains to be determined. 32 Furthermore, peripheral BDNF levels in humans are a potential biomarker for MDD and antidepressant treatment. 13, 23, 33 Thus, peripheral BDNF levels might contribute to the pathogenesis and treatment of depression and highlight that rats may be a more appropriate species to investigate the relationship between BDNF and MDD. Furthermore, rats exhibit a more extensive behavioural repertoire than mice and are considered translationally more relevant to humans. 31, [34] [35] [36] Finally, most behavioural tests are designed to characterise rat behaviour, 34 making the interpretation of BDNF mouse studies difficult. 
| Sucrose preference test
The sucrose preference test (SPT) measures the hedonic state of each animal. 41 Rats were habituated to drink a palatable sucrose solution (1.5%) for 2 days. A bottle of water and a bottle of the sucrose solution were made available in the animals' home cage. One and a half days after habituation, animals were single-housed and exposed to two bottles, one with water and one with the sucrose solution, for 48 hours. Bottle position (left/right) was counterbalanced across cages and switched after 24 hours during habituation and test phase.
Water and sucrose solution consumption, body weight and food intake were measured after 48 hours.
| Elevated plus-maze
Anxiety-related behaviour was assessed in the elevated plus-maze 
| Novelty induced hypophagia
The novelty induced hypophagia (NIH) task tested anhedonic-like behaviour (decreased motivation to consume a reward) and anxiety- 
| Spontaneous alternation behaviour test
The spontaneous alternation behaviour (SAB) task assesses working memory in rodents. 43 The SAB test was carried out 5 days after the NIH task and according to Henningsen et al. 44 Animals were acclimatised to the testing room 45 minutes prior to testing. Light intensity was 10 to 13 lx in the arms (49 cm length, 17 cm width, 32 cm height) and 17 lx in the triangular centre of the Y-shaped maze (120 angles).
Each rat was placed at the end of the same arm facing the back wall and allowed to explore the Y-maze for 10 minutes. Arm entries (all four paws in arm) were recorded using ANY-maze automatic tracking software (ANY-maze, Stoelting Co.). The primary readout was alternation ratio, which was calculated by the number of alternations (visiting all three arms consecutively) divided by the maximum possible alternation score (number of arm entries minus two). A high alternation ratio shows that the rat is not re-entering an arm that was previously visited, indicating intact working memory. The apparatus was cleaned with 70% ethanol between animals.
| Forced swim test and open field
The forced swim test (FST) is primarily used to investigate immobility behaviour (floating with minimum movements to keep the head above water) indicating a rat's propensity to surrender to a seemingly hopeless situation. On the contrary, swimming (horizontal movements throughout the cylinder) or struggling (vertical movements with the forepaws, usually against to cylinder wall) are counted as active escape attempts of the situation. Increased immobility is associated with a depressive-like phenotype. 45 The two-day FST protocol included OF testing 46, 47 
| Morris water maze
Spatial learning and memory, as well as reversal learning was examined in the MWM (2 m diameter, 0.5 m height) 48 with a naïve cohort of rats (5 WT, 10 BDNF +/− ). Rats were trained to find a hidden Atlantis escape platform (12 cm diameter; Ugo Basile, Italy) for 5 days with two trials per day. Each rat was released from one of four release points in a pre-determined random order. Rats were allowed up to 120 seconds to find and mount the platform and were guided there if they failed to find it. Latency, swim speed and distance were recorded using Actimetrics Watermaze software (Actimetrics, IL, USA). On day six (24 hours after the last test), each rat received a 60 seconds probe trial in which the escape platform was absent, but rose up after 60 seconds (to prevent extinction of the location). During the probe trial, % time spent in quadrant, % thigmotaxis (swimming within 15 cm of the pool edge), swim speed and number of platform crossings were analysed. On day seven and eight, perseverant behaviour was assessed using a reversal protocol in which the platform was moved to a randomly determined location (middle of one of the four quadrants). Rats received two swims on day seven and one swim on day eight.
To assess visual ability, a trial in which the platform was visible (ie, the water level was lowered) was conducted 2 weeks after the probe trial with curtains pulled around the maze to hide spatial cues (both groups reached the platform in under 12 AE 2 seconds; data not shown). 
| Tissue collection and RT-qPCR
behaviours, that is, swimming or struggling, in an unescapable situation. No difference between genotypes was observed for time spent immobile
| Novelty induced hypophagia is similar between genotypes
In the NIH test, the drive to consume a palatable chocolate reward competes with the fear of a novel environment and thus assesses anxiety-as well as anhedonic-like behaviour. 50 WT rats (2.77 AE 3.00 boli, Median = 2) produced significantly more faecal boli (U = 2.371, P = 0.018) than BDNF +/− rats (0.31 AE 0.63 boli, Median = 0) during testing on the EPM. Body weight of the animals, which can influence behaviour in the EPM, was not significantly different between genotypes at the time of testing. In sum, the primary readouts of the EPM suggest equal anxiety-like behaviour between genotypes, but decreased locomotor activity in the BDNF +/− rats.
| BDNF +/− rats show increased anxiety-like behaviour in open field test
The open field (OF) test assesses the conflict between anxiety-related behaviour (fear of open and lit areas) and a desire to explore. Furthermore, the OF allows assessment of locomotor activity, which could be a cofounder for behavioural testing, such as the FST. 45 BDNF +/− rats (Median = 2.10 seconds) spent less time in the centre than their WT littermates (Median = 9.70 seconds; t (12.13) = 3.31, P = 0.006; Figure 4A ). 
| Locomotor activity
As many of the tests in behavioural mazes can be confounded by the general locomotor activity of the rats, it is important to determine if there is an alteration in general activity between genotypes. There was no difference in the total distance travelled in the Y-maze (Section 3.3.1) or swim speed in the water maze (Section 3.3.2) suggesting similar locomotor activity across genotypes. However, BDNF +/− rats moved less in the OF ( Figure 4B ) and in the EPM (Section 3.2.1) compared to the WT controls. Thus, when altered locomotor activity between genotypes was present in tasks, it was accounted for in the respective analysis.
| Gene expression
To test whether reduced BDNF levels alter expression patterns of a selection of genes thought to underpin the depressive phenotype, we investigated expression of genes involved in affective disorders and relevant for an appropriate stress response in the PFC and HPC of naïve WT and BDNF +/− rats. Gene expression was upregulated in the PFC of BDNF +/− rats compared to WT animals for GR (t (17) = −2.30, P = 0.035), Nrg1 (t (17) = −2.25, P = 0.038) and Disc1 (t (17) = −4.71, Figure 6 . There were no significant differences between the mRNA levels of MR, Crh, Fkbp5 and Gsk3b in the PFC of WT and BDNF +/− rats (Table SS1 , Supporting Information). In the HPC, Fkbp5 mRNA expression was reduced in BDNF +/− animals compared to WT animals (t (9.45) = 3.09, P = 0.012; Figure 6 ). However, no significant difference in HPC mRNA expression was identified for GR, MR, Crh, Nrg1, Disc1 and Gsk3b between WT and BDNF +/− rats (Table SS1 ).
| DISCUSSION
In the present study, we showed that BDNF +/− rats display depressive-like behaviour, signs of anxiety, and altered expression of genes associated with mood disorders in the PFC and HPC compared to WT animals. However, behavioural despair and cognition was similar for BDNF +/− and WT littermates.
Depressive-like behaviour was assessed by testing for anhedonia, a core symptom of MDD. Sucrose consumption is frequently used to evaluate the hedonic state of an animal. 51 In the present study, BDNF +/− rats consumed less sucrose solution in favour of a higher water intake compared to WT controls. Hence, reduced BDNF levels resulted in an anhedonic-like state and, thus, BDNF +/− rats exhibit a depressive-like phenotype. It is possible that changes in sucrose preference may be the result of altered gustatory signalling or altered metabolic signalling in BDNF +/− rats. However, equal food intake between the groups in our experiment does not support this. Furthermore, BDNF +/− rats display changes in hedonic state in non-gustatory tasks 52 and studies altering BDNF levels extraneous to the gustatory system observe changes in sucrose consumption as well. 32, 53 Thus, behaviour. 32 The importance of the model is further emphasised by the findings that temporal KD of BDNF in the dentate gyrus of rats 53 but not mice 55 during adulthood resulted in a decrease of sucrose consumption. Finally, reduced reward sensitivity in BDNF +/− rats was also shown in a test of cocaine seeking behaviour, 52 strengthening the results of the present study.
In this study, no difference in anxiety-related behaviour was found in the EPM. In mouse studies using the EPM, peripheral BDNF administration was shown to have an anxiolytic effect 32 but comparison of BDNF +/− to WT mice generated inconsistent results. 56, 57 However, another study with BDNF +/− rats, failed to observe altered anxiety behaviour in the EPM 58 In the present study, BDNF +/− rats did not show behavioural alterations compared to controls in the FST, which is a common test used in preclinical depression research. However, the FST was developed to assess antidepressant drug efficacy rather than depression symptomatology and is sensitive to acute antidepressant treatment while only chronic treatment is efficacious in MDD patients. 45 Therefore, the FST may not be the most appropriate test for assessing the permanent effects of genetic manipulations on depressive-like behaviour.
Cognitive impairments are often seen in MDD patients 59 and reduced BDNF levels have been implicated with impaired spatial short-term memory in rats. 60 Similarly, spatial working memory was also impaired in response to stress exposure in a preclinical MDD model. 43 We found that spatial working memory was intact in the BDNF +/− group compared to WT rats as examined in the SAB test.
Furthermore, these results are supported by our finding that BDNF +/− rats displayed intact spatial learning and memory as well as normal reversal learning in the MWM test. A limitation of our MWM study is the small sample size of WT rats used. While a larger sample size would provide a greater level of confidence in our conclusions, the performance of WT rats in our study is comparable to those reported in other studies, 48 ,61 hence we tentatively conclude that spatial cognition is not impaired in BDNF +/− rats.
To understand the neurobiological underpinnings of the behavioural alterations observed in the BDNF +/− rats, we investigated mRNA levels of key genes associated with affective disorders.
Reduced BDNF levels in our model partially mimic the consequence of stress exposure 18 and, thus, expression of glucocorticoid-regulated Gene expression. Presented are the individual and group (AESEM) gene expression levels (as % of WT group mean) from the prefrontal cortex (PFC) and hippocampus (HPC). Statistical significance is indicted with *P < 0.05, ***P < 0.001 genes might be effected in our model. The PFC and HPC are key regions affected both by stress as well as in psychiatric disorders. [62] [63] [64] [65] Furthermore BDNF mRNA levels were found decreased in depressed suicide victims in these regions. 21 In the PFC, we found that GR mRNA is increased, in combination with Nrg1 and Disc1, in BDNF +/− rats compared to WT controls.
Viral Knockdown of GR in the PFC is associated with stress hyper-responsivity, reduced stress-induced affective behaviour, 66 and increased sensitivity to antidepressant treatment. 67 However, in the non-stressed situation the plasma corticosterone levels were normal in these rats. We therefore postulate that the increased GR expression in BDNF +/− rats may be a compensatory mechanism to retain normal control of the HPA axis and GR signalling in the PFC. This interpretation is supported by the finding that BDNF +/− have a similar HPA axis response to WT rats during mild stress exposure.
37
NRG1 was identified as a susceptibility gene in neuropsychiatric diseases in humans, it drives neuronal plasticity and is associated with cognitive impairments. 68 However, in the chronic unpredicatable stress (CUS) model of depression in rats, NRG1 protein was significantly increased in the PFC. 69 This increased PFC NRG1 expression parallels the results found in our BDNF +/− model and implies increased PFC Nrg1 expression may contribute to the observed depressive-like phenotype in our model.
In schizophrenia, bipolar disorder and MDD, translocation and loss of function of DISC1 was shown. [70] [71] [72] Overexpression of Disc1 in the mouse ventral HPC resulted in a depressive-like phenotype. 73 In our study, we found that Disc1 expression was elevated in the PFC of the BDNF +/− rats. Viral knockdown of Disc1 solely in the PFC increased susceptibility to stress-induced PFC dysfunction, 74 which may explain why patients with DISC1 mutations are especially vulnerable to stress. Conversely, when DISC1 is overexpressed, mimicking a failure of DISC1 proteostasis, characteristics of mental disorders are found in behaviour, brain structure and in synaptic processes including membrane trafficking and synaptic organisation. 75 Therefore, PFC Disc1 overexpression in BDNF +/− rats is potentially consistent with underpinning an increased risk of schizophrenia and depression. DISC1 regulates GSK3B and altered expression pattern in the latter one was associated with neuropsychiatric diseases, such as MDD and anxiety disorder. 76 Furthermore, reduced
Gsk3b expression can be found in the HPC following stress exposure in mice, 77 whereas altered GSK3B in the PFC affects mood and is suggested relevant for the antidepressant response. 78 However, in this study
Gsk3b expression was not altered in the BDNF +/− rat brain.
The hippocampus is a region of the brain known to be important for regulation of the HPA axis and also is very sensitive to the action of glucocorticoids, which affect cognitive and affective behaviours. BDNF +/− rats exhibited normal expression of GR, but a decrease in hippocampal Fkbp5 mRNA. FKBP5 is a heat shock protein 90 cochaperone and the complex competes with glucocorticoids for binding to GR and, thus, modifies GR sensitivity and its function as a transcription factor. 79, 80 Furthermore, GR activity increases FKBP5 expression, providing an ultra short feedback loop for GR sensitivity. 79 Polymorphisms in FKBP5 leading to an increased expression of the gene were found in MDD patients and associated with a prolonged stress response. 79 However, as HPA axis response 37 and hippocampal GR, MR and Crh mRNA levels are normal in the BDNF +/− rats, the mechanistic relevance of the decreased Fkbp5 mRNA expression remains to be determined. The unexpected finding that expression of key genes, known to be regulated in depressive-like phenotypes, were not regulated in the hippocampus of BDNF +/− rats is surprising. However, as the hippocampus is a large heterogeneous structure, 81 it is possible that using whole hippocampal samples in this study precludes detecting subtle differences in gene expression levels that may only be present in specific hippocampal subregions.
We have previously showed that BDNF +/− rats exhibit 30% to 70% reduced brain and serum levels of BDNF protein, 37 but due to the ZFN technology used to engineer this genetic modification, this is not reflected in a change of BDNF mRNA levels. Unfortunately, this precludes determination of correlations between regional brain BDNF mRNA levels in BDNF +/− rats with behavioural outcomes or expression of key genes measured in this study.
Overall, we have shown that a genetically induced reduction of BDNF levels lead to a depressive-like phenotype as well as to alterations in expression levels of genes that are relevant for psychiatric disorders. In future studies, testing of female rats should be included due to sex differences observed in MDD prevalence in humans. 82 Furthermore, a combination of stress and genetic manipulation might be ideal to provoke a more differentiated phenotype. However, the present study established a solid basis for future research, with the rat as a better model for preclinical studies than the abundantly studied mouse, due the similarity of BDNF expression in rats and humans and the reproducibility of findings in the rat but not in the mouse. Moreover, our study suggests a link of decreased BDNF levels with the MDD core symptom of anhedonia. It is also showed that changes in BDNF signalling result in altered expression of Disc1, Nrg1, GR and 
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